ASCO 2023 | ASCO 2023 rare lymphoma highlights: JACKPOT8, IELSG37, and mogamulizumab + CHOP in ATL
Neha Mehta-Shah, MD, Washington University in St Louis, St Louis, MO, comments on the results of three studies in rare lymphomas presented at this year’s American Society of Clinical Oncology (ASCO) meeting. Dr Mehta-Shah first discusses the Phase I/II JACKPOT8 trial (NCT04105010), investigating golidocitinib, a JAK inhibitor for relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL). Secondly, Dr Mehta-Shah comments on a study exploring the combination of mogamulizumab with CHOP for newly diagnosed, transplant-ineligible patients with acute T-cell leukemia/lymphoma (ATL). Finally, Dr Mehta-Shah highlights the Phase III IELSG37 trial (NCT01599559), examining the potential of omitting consolidation radiation therapy for patients with primary mediastinal large B-cell lymphoma (PMBCL) who achieve PET negativity after standard chemoimmunotherapy. This interview took place at the ASCO 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
